Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
In pre-clinical studies DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy.
Lead Product(s): DT2216
Therapeutic Area: Oncology Product Name: DT2216
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
Dialectic will use the funding to further the development of its lead product candidate, DT2216.
Lead Product(s): DT2216
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Cancer Prevention & Research Institute of Texas
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 26, 2020